Study Phase II / III, multicenter, double-masked, randomized, parallel Group, with variations of dose, controlled to evaluate the efficacy and safety of NOVA22007 (eye cationic emulsion of Cyclosporine A (CSA) 00:05% and 0.1%) vs. vehicle in patients with vernal queratoconjonctivitis. [Estudio de fase II/III, Multicentrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dosis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsion ocular cationica de Ciclosporina A (CSA) 0.05% y 0.1%) frente a vehiculo en pacientes con queratoconjonctivitis vernal.]

Trial Profile

Study Phase II / III, multicenter, double-masked, randomized, parallel Group, with variations of dose, controlled to evaluate the efficacy and safety of NOVA22007 (eye cationic emulsion of Cyclosporine A (CSA) 00:05% and 0.1%) vs. vehicle in patients with vernal queratoconjonctivitis. [Estudio de fase II/III, Multicentrico, doble enmascarado, Aleatorizado, de Grupos paralelos, Con variacion de dosis, controlado para valorar la eficacia y seguridad de NOVA22007 (emulsion ocular cationica de Ciclosporina A (CSA) 0.05% y 0.1%) frente a vehiculo en pacientes con queratoconjonctivitis vernal.]

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 09 Sep 2014

At a glance

  • Drugs Ciclosporin (Primary)
  • Indications Allergic conjunctivitis
  • Focus Therapeutic Use
  • Sponsors Santen S.A.S.
  • Most Recent Events

    • 09 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top